Product Images Escitalopram Oxalate

This is a medication called Escitalopram, available only with a prescription. It has an NDC number and an expiration date, as well as a lot number and a source NDC number. It is manufactured by Cipla USA Inc. and should be kept away from children. The medication should be stored between 20-26°C (63-77°F), with short excursions permitted to 15-30°C (59-86°F), as per USP guidelines. It is recommended to consult the package insert for directions on how to use. The medication has been repackaged by RemedyRepack Inc. located in Indiana, PA.*

This is a description of a medication called Escitalopram. It is available only with a prescription and comes in a package with an NDC number of 70518-3151-00, an expiration date, and a LOT number. It is made by Cipla USA, Inc. and should be kept out of reach of children. The directions for use are found in the package insert. It should be stored at a temperature between 20-26°C, with excursions of 15-30°C permitted (as per USP guidelines). It has been repackaged by RemedyRepack Inc. in Indiana, PA.*

This text appears to be a table presenting data related to the effect of a drug on suicidality in patients of different age ranges. The drug seems to increase the number of cases of suicidality in patients under 18 compared to placebo treatment, while it decreases the number of cases in patients over 65. The text provides details on the difference in the number of cases of suicidality per 1000 patients treated.*

This table presents treatment-emergent adverse reactions with a frequency of greater than 2% and higher than placebo for Major Depressive Disorder. The table compares the percentage of adverse reactions between Escitalopram and Placebo. The adverse reactions are classified according to different body systems or disorders, including Autonomic Nervous System and Central & Peripheral Nervous System Disorders, Gastrointestinal Disorders, General disorders, Psychiatric Disorders, Respiratory System Disorders, and Urogenital. Some of the adverse reactions include dry mouth, sweating increased, dizziness, nausea, diarrhea, constipation, fatigue, insomnia, somnolence, rhinitis, sinusitis, and ejaculation disorder. The text also mentions that the denominator used was for males only for ejaculation disorder and for females only for anorgasmia.*

This is an excerpt from a table showing the treatment-emergent adverse reactions observed with a frequency of greater than 2% and greater than placebo for Generalized Anxiety Disorder. The table shows the adverse reactions observed with Escitalopram and Placebo for each category of disorders such as Autonomic Nervous System Disorders, Central & Peripheral Nervous System Disorders, etc. The adverse reactions and their corresponding percentages are listed within each disorder category. The adverse reactions included Nausea, Dry mouth, Insomnia, Headache, and others. In some cases, the denominator for the percentage is specified for males or females.*

The table shows the incidence of common adverse reactions in patients with Major Depressive Disorder taking either placebo, 10mg/day or 20mg/day of Escitalopram. The adverse reactions are listed and the percentage of each reaction is given for each treatment group. The adverse reactions include insomnia, diarrhea, dry mouth, somnolence, dizziness, sweating increased, constipation, fatigue, and indigestion.*

The text describes a table showing the incidence of sexual side effects in placebo-controlled clinical trials for Escitalopram versus Placebo in Wales. It provides data on adverse events, ejaculation disorder, ejaculatory delay, libido decrease, impotence, and anorgasmia, with corresponding percentages for each.*